Mereo BioPharma Group

Mereo BioPharma Group

MREO· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -88.1% in FY2025

Dr. Denise Scots-Knight is the CEO of Mereo BioPharma Group and was paid $2.7M in FY2025 (Dec), down 14%.

Pay$100 in the stock at the end of FY22 → $56
CEO pay is from each Mereo BioPharma Group proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Dr. Denise Scots-KnightFY2025
  2. 2Charles SermonFY2025
  3. 3Christine FoxFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Mereo BioPharma Group paid its 3 named executives $5.0M in total in FY2025 (Dec). CEO Dr. Denise Scots-Knight was paid $2.7M of that.

Name
Dr. Denise Scots-KnightChief Executive Officer
Charles SermonGeneral Counsel
Christine FoxChief Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Mereo BioPharma Group. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board5

See all
  • Anders EkblomDirector · 9 yr on the boardIndependentRemuneration (Chair), Research and Development (Chair)—Paid as an executive
  • Jeremy BenderDirector · 4 yr on the boardIndependentAudit and Risk, Nomination and Corporate Governance—Paid as an executive
  • Annalisa JenkinsDirector · 2 yr on the boardIndependentAudit and Risk—Paid as an executive
  • Daniel ShamesDirector · 2 yr on the boardIndependentResearch and Development—Paid as an executive
  • Justin RobertsDirector · 2 yr on the boardIndependentNomination and Corporate Governance, Remuneration—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. PayDEF 14A
  2. PayDEF 14A
  3. PayDEF 14A
  4. PayDEF 14A
  5. PayDEF 14A
  6. PayDEF 14A
  7. PayDEF 14A
  8. PayDEF 14A

Filings6

See all
Proxy statementDEF 14AApr 9, 2026FY2025
Annual report10-KMar 19, 2026FY2025
Proxy statementDEF 14AApr 8, 2025FY2024
Annual report10-KMar 26, 2025FY2024
Proxy statementDEF 14AApr 24, 2024FY2023
Annual report10-KMar 27, 2024FY2023